An observational study in Subjective Cognitive Decline (SCD), sponsored by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation. Not yet recruiting at 1 site in Spain. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.
Sponsored by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Alzheimer Disease by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation — 5 open to participants now, 7 under way, none of them phase 3. Alzheimer Disease · Barcelonabeta Brain Research Center, Pasqual Maragall Foundation.
Among the 15 studies in Alzheimer Disease by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation, this one is one of 3 that started in 2026, is one of 9 observational ones, and was the 15th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →5 of the 15 studies in Alzheimer Disease by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation are open now, in 1 country. Recruiting first, the newest first:
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Sites in Spain
Ages 55–85
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Sites in Spain
Ages 45+ · Healthy volunteers
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Sites in Spain
Ages 45–75 · Healthy volunteers
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Sites in Spain
Ages 50–75 · Healthy volunteers
By country, each count listing its studies:
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 121 is below the median of 200 across 817 observational studies indexed under Alzheimer Disease.
Median enrollment 176 across the 6 interventional studies, 250 across the 9 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation is the lead sponsor of 22 studies on the registry; 7 are open to participants now.
4 of the studies in Alzheimer Disease by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02685969Barcelonabeta Brain Research Center, Pasqual Maragall FoundationBrain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants | 2026-12-31 |
| NCT03851523Barcelonabeta Brain Research Center, Pasqual Maragall FoundationLongitudinal Study for the Characterization of the Phases of Subjective Perception of Cognitive Decline and Mild Cognitive Impairment of Alzheimer's Disease. | 2026-12-31 |
| NCT07521722Barcelonabeta Brain Research Center, Pasqual Maragall FoundationDIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community | 2027-04-27 |
| NCT07730671Barcelonabeta Brain Research Center, Pasqual Maragall FoundationPENSA+: Extended Follow-up of a Multimodal Lifestyle Intervention to Prevent Cognitive Decline in APOE-ε4 Carriers | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 15 studies in Alzheimer Disease by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
PENSA+ is a 5-year follow-up study of participants who previously completed the PENSA clinical trial (NCT03978052), which evaluated an intensive multimodal lifestyle intervention, with or without epigallocatechin gallate (EGCG), in APOE-ε4 carriers with subjective cognitive decline, a population at increased risk of developing Alzheimer's disease.
The purpose of this study is to determine whether the cognitive, biological, and lifestyle benefits observed after the original intervention are maintained over the long term. Researchers will evaluate cognitive performance, the incidence of mild cognitive impairment, dementia risk, brain imaging, blood biomarkers, physical fitness, lifestyle behaviors, and psychosocial factors approximately five years after completion of the intervention.
The study will also investigate the biological and behavioral mechanisms associated with sustained cognitive benefit, identify participant characteristics associated with better long-term outcomes, evaluate the long-term cost-effectiveness of the intervention using healthcare utilization data, and explore whether lifestyle changes have influenced participants' study partners. No new intervention will be administered as part of this follow-up study.
Alzheimer's disease (AD) is the leading cause of dementia and is characterized by a long preclinical phase during which pathological changes accumulate before the onset of clinical symptoms. This extended asymptomatic period provides an opportunity to implement preventive strategies aimed at delaying or reducing cognitive decline. Multidomain lifestyle interventions targeting modifiable risk factors have emerged as one of the most promising approaches for dementia prevention, demonstrating beneficial effects on cognitive performance and overall brain health, particularly in individuals at increased risk of developing AD. However, the long-term durability of these effects, the biological mechanisms underlying sustained benefit, the characteristics of individuals most likely to respond, and the long-term economic value of these interventions remain incompletely understood.
The PENSA+ study is a long-term follow-up of the PENSA randomized clinical trial (NCT03978052), which evaluated an intensive personalized multimodal lifestyle intervention in cognitively unimpaired APOE-ε4 carriers with subjective cognitive decline. The intervention combined dietary counseling, physical exercise, cognitive training, psychoeducation, social stimulation, and vascular risk management, and was administered with either epigallocatechin gallate (EGCG)-a naturally occurring green tea polyphenol with antioxidant, anti-inflammatory, metabolic, vascular, and potential neuroprotective properties-or placebo. Participants assigned to the control group received general healthy lifestyle recommendations. The original trial demonstrated improvements in cognitive performance, lifestyle behaviors, physical fitness, cardiometabolic health, and dementia risk in the intervention groups, with cognitive and lifestyle benefits persisting beyond the active intervention period. However, whether these benefits are maintained over the longer term and the mechanisms responsible for their persistence remain unknown.
The primary objective of PENSA+ is to evaluate cognitive performance, the incidence of mild cognitive impairment, and dementia risk approximately five years after completion of the original intervention. Secondary objectives are to investigate the biological, behavioral, and psychosocial mechanisms associated with sustained cognitive benefit, identify long-term responder phenotypes, and evaluate the long-term cost-effectiveness and cost-utility of the intervention. Exploratory objectives include assessing long-term clinical outcomes and healthcare resource utilization through electronic health records for up to 10 years after the intervention and evaluating potential spillover effects on participants' study partners.
Participants who completed the original PENSA trial will undergo comprehensive follow-up evaluations, including cognitive, neurological, neuroimaging, biomarker, physical fitness, lifestyle, and psychosocial assessments. Data collected during the original trial will be integrated with the five-year follow-up data to characterize long-term cognitive trajectories, identify determinants of sustained cognitive resilience, and provide evidence on the long-term clinical and economic impact of intensive multidomain lifestyle interventions for Alzheimer's disease prevention.
Individuals who previously completed the PENSA study will constitute the target population of this study.
Of the 129 participants initially enrolled in the PENSA study, 121 completed it.
Participants who completed the PENSA study were allocated as follows:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Any individual who has completed the PENSA study, does not meet any exclusion criteria, and provides consent is eligible to participate in this study.
Exclusion Criteria
Participants will be excluded from the study if they meet any of the following conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who completed the original PENSA trial and were assigned to the intensive personalized multimodal lifestyle intervention combined with epigallocatechin gallate (EGCG) supplementation for 12 months. The intervention included dietary counseling, physical exercise, cognitive training, psychoeducation, social stimulation, and vascular risk management. Participants are followed approximately 5 years after completion of the intervention (current PENSA+ study) to evaluate long-term cognitive, biological, lifestyle, and health outcomes.
Participants who completed the original PENSA trial and were assigned to the intensive personalized multimodal lifestyle intervention combined with placebo supplementation for 12 months. The intervention included dietary counseling, physical exercise, cognitive training, psychoeducation, social stimulation, and vascular risk management. Participants are followed approximately 5 years after completion of the intervention (current PENSA+ study) to evaluate long-term cognitive, biological, lifestyle, and health outcomes.
Participants who completed the original PENSA trial and were assigned to the control group, receiving general healthy lifestyle recommendations without the intensive multimodal intervention. Participants are followed approximately 5 years after completion of the original study (current PENSA+ study) to evaluate long-term cognitive, biological, lifestyle, and health outcomes.
Global Cognitive Performance (PACC-exe Composite Score)
Global cognitive performance assessed using the Preclinical Alzheimer Cognitive Composite for executive function, a composite score derived from six neuropsychological tests: Montreal Cognitive Assessment (score 0-30, higher scores indicate better cognition), Free and Cued Selective Reminding Test (score 0-48, higher scores indicate better episodic memory), Logical Memory Delayed Recall from the Wechsler Memory Scale (score 0-48, higher scores indicate better delayed verbal memory), WAIS-IV Coding (higher scores indicate better processing speed), Stroop Color-Word Test Interference score (higher scores indicate better inhibitory control and executive function), and Five Digit Test (higher scores indicate better executive functioning and cognitive flexibility). Individual test scores are converted to standardized z-scores based on the baseline mean and standard deviation of the study cohort, and the PACC-exe score is calculated as the arithmetic mean of these z-scores.
Time frame: Baseline, 12 months, and approximately 5 years after completion of the original PENSA intervention
Incidence of Mild Cognitive Impairment (MCI)
Incidence of Mild Cognitive Impairment determined according to clinical diagnostic criteria based on neuropsychological evaluation and clinical assessment performed at the 5-year follow-up visit. Diagnosis will require: (1) evidence of objective cognitive impairment on standardized neuropsychological assessment; (2) reported cognitive decline from previous functioning by the participant, an informant, or documented longitudinal assessment; (3) preserved independence in activities of daily living (impaired performance will be defined as below the 10th percentile, scaled score \<7, or ≥1.3 SD below age- and education-adjusted normative means); and (4) absence of dementia. Domain-specific impairment will be defined as low performance in ≥3 of 5 memory measures, ≥3 of 5 executive function measures, or ≥2 of 2 language measures. Final diagnosis will be established by a neurologist based on the integrated evaluation of neuropsychological, clinical, functional, and behavioral information.
Time frame: Approximately 5 years after completion of the original PENSA intervention
Dementia Risk (LIBRA Index)
Dementia risk assessed using the Lifestyle for Brain Health (LIBRA) Index, a weighted composite score of modifiable risk and protective factors for dementia. Lower scores indicate lower estimated dementia risk. The dementia risk assessed with the LIBRA Index is a weighted composite score of 12 modifiable risk and protective factors for dementia. These modifiable risks are the following: 1. Coronary heart disease 2. Chronic kidney disease 3. Hypertension 4. Hypercholesterolemia 5. Diabetes 6. Depression 7. High cognitive activity 8. Obesity 9. Low/moderate alcohol use 10. Physical inactivity 11. Smoking 12. Healthy diet
Time frame: Baseline, 12 months, and approximately 5 years after completion of the original PENSA intervention
Longitudinal changes in memory and executive function
Longitudinal changes in cognitive domains (memory and executive function scores, PMCID: PMC12413734).
Time frame: Baseline, 12-month, 5-year
Longitudinal changes in Mediterranean diet adherence
Diet will be assessed through Mediterranean Diet Adherence Screener (MEDAS-14). The MEDAS-14 is a 14-item questionnaire for the assessment of Mediterranean diet compliance. It has been developed and validated by researchers of the PREDIMED study (PMCID: PMC8710807). The maximum possible score is 14 points. This questionnaire allows the participants to be classified according to their adherence to the Mediterranean diet, being appropriate if the score is ≥10 or not appropriate if the score is \<10.
Time frame: Baseline, 12-month, 5-year
Longitudinal changes in physical activity
Physical activity is measure through the Short Minnesota Leisure Time Activities Questionnaire (VREM). The VREM questionnaire asks for information on six activities carried out in the last month (or usual month) in order to find out the level of PA performed: walking, gardening in the garden, doing sport or dancing, climbing stairs, shopping on foot, and cleaning the house. cleaning the house (PMID: 23223762). According to the number of minutes spent on each activity and the frequency they are carried out over the course of a year, the energy expenditure is estimated for 14 days, expressed in Metabolic Equivalents (METs) per minute per 14 days (MET-min-14 days). The VREM makes it possible to distinguish between very active (more than 5,000 MET-min-14 days), active (between 3,000 and 4,999), moderately active (between 1,250 and 2,999), and sedentary (less than 1,250).
Time frame: Baseline, 12-month, 5-year
Longitudinal changes in quality of life
Quality of life is measured through the World Health Organization Quality of Life (WHOQOL)-BREF. The WHOQOL-BREF comprises 26 items, categorized into four domains: physical health (7 items), psychological well-being (6 items), social connections (3 items), and environmental health (8 items) (PMID: 15085902). Additionally, it includes items addressing the overall quality of life and general health. Each item in the WHOQOL-BREF is assessed on a five-point ordinal scale. These scores are then linearly transformed to a 0-100 scale. The physical health domain encompasses aspects such as mobility, daily activities, functional capacity, energy, pain, and sleep. Within the psychological domain, assessments cover self-image, negative thoughts, positive attitudes, self-esteem, mentality, learning ability, memory concentration, religion, and mental status. The social relationships domain explores personal relationships, social support, and aspects of one's sex life.
Time frame: Baseline, 12-month, 5-year
Longitudinal changes in physical fitness - Senior Fitness Test
Physical fitness will be assessed using the Senior Fitness Test (SFT), a standardized battery that evaluates overall physical fitness in older adults, including muscle strength, aerobic endurance, flexibility, agility, and dynamic balance. Higher scores in the SFT indicate better physical fitness.
Time frame: Baseline, 12-month, 5-year
Longitudinal changes in physical fitness - Grip Strength Test
Physical Fitness will be assessed with the Grip Strength Test. For this test, the best result from 3 trials for each hand will be recorded and summed.
Time frame: Baseline, 12-month, 5-year
Longitudinal Changes in Plasma Alzheimer's Disease Biomarkers and Neuroimaging Measures
Change and trajectory in plasma AD biomarkers and neuroimaging measures of brain structure and function. Specifically, plasma AD biomarkers include the concentration levels of phosphorylated tau (p-tau217 and p-tau181), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP), all expressed in pg/mL, as well as the amyloid-β 42/40 ratio. Simultaneously, neuroimaging markers derived from structural MRI include hippocampal, lateral ventricular volumes, and White Matter Hyperintensities (WMH) - all normalized to total intracranial volume (TIV)-, and a composite measure of cortical thickness in "AD-signature" regions (PMID: 21490323).
Time frame: Baseline, 12-month, 5-year
Economic Outcomes: Long-term Cost-Effectiveness and Cost-Utility
Incremental cost-effectiveness ratios (ICERs) expressed as cost per unit improvement in global cognitive performance (PACC-exe), and the Incremental Cost-Utility Ratio (ICUR), expressed as the cost per Quality-Adjusted Life Year (QALY) gained based on EQ-5D-5L data.
Time frame: Baseline, 12 months, and approximately 5 years after completion of the original PENSA intervention
Longer-term Clinical Outcomes and Healthcare Utilization Using EHRs (up to 10 years of follow-up)
Incidence of all-cause dementia and AD identified via validated Electronic Health Record (EHR) algorithms. Time-to-event methods will be used where feasible to analyze longer-term incidence outcomes. Kaplan-Meier curves and Cox proportional hazards models, or alternative parametric/survival models if proportional hazards assumptions are not met, will be used to compare intervention groups with adjustment for baseline covariates. If event dates are not sufficiently precise or follow-up intervals are irregular, discrete-time survival models or regression models for cumulative incidence may be used instead. Longer-term healthcare utilization will be summarized descriptively and analyzed using count models (e.g., Poisson or negative binomial regression) or generalized estimating equations, as appropriate to the distribution of the data.
Time frame: Baseline and within 10 years forward based on EHR
Spillover Effect on study partners - Mediterranean diet adherence
Concordance between participants and their study partners regarding Mediterranean diet adherence, measured through the Mediterranean Diet Adherence Screener (MEDAS-14).
Time frame: Approximately 5 years after termination of PENSA
Spillover effect on study partners - physical activity levels
Concordance between participants and their study partners regarding physical activity adherence, measured through the Short Minnesota Leisure Time Activities Questionnaire (VREM).
Time frame: Approximately 5 years after termination of PENSA
Spillover Effect on study partners - cognitive engagement
Concordance between participants and their study partners regarding cognitive engagement, which is measured through the Lifestyle Activities Questionnaire (LAQ). Cognitive and social activity will be measured using a questionnaire that results from the translation and adaptation of the LAQ. The LAQ is used to assess a participant's engagement in various daily activities with different cognitive demands, such as reading, playing musical instruments, or attending social gatherings. This questionnaire allows the quantification of both the frequency and the variety of these activities. A greater variety of participation in activities, as assessed by LAQ, was associated with reduced cognitive impairment (PMCID: PMC3508669).
Time frame: Approximately 5 years after termination of PENSA.
Plan to share: No
Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.
Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 12 months is below that.
Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation